Chargement en cours...
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE-Hindawi Access to Research
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3170848/ https://ncbi.nlm.nih.gov/pubmed/21994874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2011/873548 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|